Joseph Colgan (Q45420): Difference between revisions
From geokb
(Changed an Item: Added OpenAlex ID) |
(Changed label, description and/or aliases in en, and other parts: Updated OpenAlex topics from API) |
||||||||||||||
aliases / en / 0 | aliases / en / 0 | ||||||||||||||
Joseph Colgan | |||||||||||||||
aliases / en / 1 | aliases / en / 1 | ||||||||||||||
Joseph P. Colgan | |||||||||||||||
aliases / en / 2 | aliases / en / 2 | ||||||||||||||
J D Colgan | |||||||||||||||
aliases / en / 3 | aliases / en / 3 | ||||||||||||||
J. P. Colgan | |||||||||||||||
aliases / en / 4 | aliases / en / 4 | ||||||||||||||
J. Colgan | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Lymphoid Neoplasms / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Lymphoid Neoplasms / qualifier | |||||||||||||||
point in time: 17 May 2024
| |||||||||||||||
Property / knows about: Lymphoid Neoplasms / qualifier | |||||||||||||||
prevalence: 105
| |||||||||||||||
Property / knows about: Lymphoid Neoplasms / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Tectonic and Geochronological Evolution of Orogens / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Tectonic and Geochronological Evolution of Orogens / qualifier | |||||||||||||||
point in time: 17 May 2024
| |||||||||||||||
Property / knows about: Tectonic and Geochronological Evolution of Orogens / qualifier | |||||||||||||||
prevalence: 59
| |||||||||||||||
Property / knows about: Tectonic and Geochronological Evolution of Orogens / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Machine Learning for Mineral Prospectivity Mapping / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Machine Learning for Mineral Prospectivity Mapping / qualifier | |||||||||||||||
point in time: 17 May 2024
| |||||||||||||||
Property / knows about: Machine Learning for Mineral Prospectivity Mapping / qualifier | |||||||||||||||
prevalence: 47
| |||||||||||||||
Property / knows about: Machine Learning for Mineral Prospectivity Mapping / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia / qualifier | |||||||||||||||
point in time: 17 May 2024
| |||||||||||||||
Property / knows about: Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia / qualifier | |||||||||||||||
prevalence: 45
| |||||||||||||||
Property / knows about: Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Viral-Related Cancers in Immunocompromised Patients / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Viral-Related Cancers in Immunocompromised Patients / qualifier | |||||||||||||||
point in time: 17 May 2024
| |||||||||||||||
Property / knows about: Viral-Related Cancers in Immunocompromised Patients / qualifier | |||||||||||||||
prevalence: 32
| |||||||||||||||
Property / knows about: Viral-Related Cancers in Immunocompromised Patients / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Seismicity and Tectonic Plate Interactions / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Seismicity and Tectonic Plate Interactions / qualifier | |||||||||||||||
point in time: 17 May 2024
| |||||||||||||||
Property / knows about: Seismicity and Tectonic Plate Interactions / qualifier | |||||||||||||||
prevalence: 30
| |||||||||||||||
Property / knows about: Seismicity and Tectonic Plate Interactions / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Climate Change and Paleoclimatology / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Climate Change and Paleoclimatology / qualifier | |||||||||||||||
point in time: 17 May 2024
| |||||||||||||||
Property / knows about: Climate Change and Paleoclimatology / qualifier | |||||||||||||||
prevalence: 27
| |||||||||||||||
Property / knows about: Climate Change and Paleoclimatology / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Diagnosis and Treatment of Primary Central Nervous System Lymphoma / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Diagnosis and Treatment of Primary Central Nervous System Lymphoma / qualifier | |||||||||||||||
point in time: 17 May 2024
| |||||||||||||||
Property / knows about: Diagnosis and Treatment of Primary Central Nervous System Lymphoma / qualifier | |||||||||||||||
prevalence: 14
| |||||||||||||||
Property / knows about: Diagnosis and Treatment of Primary Central Nervous System Lymphoma / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Advancements in Lung Cancer Research / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Advancements in Lung Cancer Research / qualifier | |||||||||||||||
point in time: 17 May 2024
| |||||||||||||||
Property / knows about: Advancements in Lung Cancer Research / qualifier | |||||||||||||||
prevalence: 9
| |||||||||||||||
Property / knows about: Advancements in Lung Cancer Research / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Natural Killer Cells in Immunity / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Natural Killer Cells in Immunity / qualifier | |||||||||||||||
point in time: 17 May 2024
| |||||||||||||||
Property / knows about: Natural Killer Cells in Immunity / qualifier | |||||||||||||||
prevalence: 9
| |||||||||||||||
Property / knows about: Natural Killer Cells in Immunity / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Sedimentary Processes in Earth's Geology / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Sedimentary Processes in Earth's Geology / qualifier | |||||||||||||||
point in time: 17 May 2024
| |||||||||||||||
Property / knows about: Sedimentary Processes in Earth's Geology / qualifier | |||||||||||||||
prevalence: 9
| |||||||||||||||
Property / knows about: Sedimentary Processes in Earth's Geology / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: mTOR Signaling in Growth and Disease / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: mTOR Signaling in Growth and Disease / qualifier | |||||||||||||||
point in time: 17 May 2024
| |||||||||||||||
Property / knows about: mTOR Signaling in Growth and Disease / qualifier | |||||||||||||||
prevalence: 8
| |||||||||||||||
Property / knows about: mTOR Signaling in Growth and Disease / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Geological Modeling and Uncertainty Analysis / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Geological Modeling and Uncertainty Analysis / qualifier | |||||||||||||||
point in time: 17 May 2024
| |||||||||||||||
Property / knows about: Geological Modeling and Uncertainty Analysis / qualifier | |||||||||||||||
prevalence: 7
| |||||||||||||||
Property / knows about: Geological Modeling and Uncertainty Analysis / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Epidemiology of Multiple Primary Cancers / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Epidemiology of Multiple Primary Cancers / qualifier | |||||||||||||||
point in time: 17 May 2024
| |||||||||||||||
Property / knows about: Epidemiology of Multiple Primary Cancers / qualifier | |||||||||||||||
prevalence: 6
| |||||||||||||||
Property / knows about: Epidemiology of Multiple Primary Cancers / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Chimeric Antigen Receptor T Cell Therapy / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Chimeric Antigen Receptor T Cell Therapy / qualifier | |||||||||||||||
point in time: 17 May 2024
| |||||||||||||||
Property / knows about: Chimeric Antigen Receptor T Cell Therapy / qualifier | |||||||||||||||
prevalence: 6
| |||||||||||||||
Property / knows about: Chimeric Antigen Receptor T Cell Therapy / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Therapeutic Antibodies: Development, Engineering, and Applications / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Therapeutic Antibodies: Development, Engineering, and Applications / qualifier | |||||||||||||||
point in time: 17 May 2024
| |||||||||||||||
Property / knows about: Therapeutic Antibodies: Development, Engineering, and Applications / qualifier | |||||||||||||||
prevalence: 5
| |||||||||||||||
Property / knows about: Therapeutic Antibodies: Development, Engineering, and Applications / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Gliomas / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Gliomas / qualifier | |||||||||||||||
point in time: 17 May 2024
| |||||||||||||||
Property / knows about: Gliomas / qualifier | |||||||||||||||
prevalence: 5
| |||||||||||||||
Property / knows about: Gliomas / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Immunobiology of Dendritic Cells / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Immunobiology of Dendritic Cells / qualifier | |||||||||||||||
point in time: 17 May 2024
| |||||||||||||||
Property / knows about: Immunobiology of Dendritic Cells / qualifier | |||||||||||||||
prevalence: 5
| |||||||||||||||
Property / knows about: Immunobiology of Dendritic Cells / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Diagnosis and Treatment of Multiple Myeloma / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Diagnosis and Treatment of Multiple Myeloma / qualifier | |||||||||||||||
point in time: 17 May 2024
| |||||||||||||||
Property / knows about: Diagnosis and Treatment of Multiple Myeloma / qualifier | |||||||||||||||
prevalence: 5
| |||||||||||||||
Property / knows about: Diagnosis and Treatment of Multiple Myeloma / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Geological Evolution of the Arctic Region / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Geological Evolution of the Arctic Region / qualifier | |||||||||||||||
point in time: 17 May 2024
| |||||||||||||||
Property / knows about: Geological Evolution of the Arctic Region / qualifier | |||||||||||||||
prevalence: 5
| |||||||||||||||
Property / knows about: Geological Evolution of the Arctic Region / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Mantle Dynamics and Earth's Structure / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Mantle Dynamics and Earth's Structure / qualifier | |||||||||||||||
point in time: 17 May 2024
| |||||||||||||||
Property / knows about: Mantle Dynamics and Earth's Structure / qualifier | |||||||||||||||
prevalence: 5
| |||||||||||||||
Property / knows about: Mantle Dynamics and Earth's Structure / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Diversity and Applications of Cyperus Species / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Diversity and Applications of Cyperus Species / qualifier | |||||||||||||||
point in time: 17 May 2024
| |||||||||||||||
Property / knows about: Diversity and Applications of Cyperus Species / qualifier | |||||||||||||||
prevalence: 5
| |||||||||||||||
Property / knows about: Diversity and Applications of Cyperus Species / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Cancer Immunotherapy / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Cancer Immunotherapy / qualifier | |||||||||||||||
point in time: 17 May 2024
| |||||||||||||||
Property / knows about: Cancer Immunotherapy / qualifier | |||||||||||||||
prevalence: 5
| |||||||||||||||
Property / knows about: Cancer Immunotherapy / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Characterization of Shale Gas Pore Structure / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Characterization of Shale Gas Pore Structure / qualifier | |||||||||||||||
point in time: 17 May 2024
| |||||||||||||||
Property / knows about: Characterization of Shale Gas Pore Structure / qualifier | |||||||||||||||
prevalence: 5
| |||||||||||||||
Property / knows about: Characterization of Shale Gas Pore Structure / reference | |||||||||||||||
Property / knows about | |||||||||||||||
Property / knows about: Human T-cell Leukemia Virus Type 1 Infection / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / knows about: Human T-cell Leukemia Virus Type 1 Infection / qualifier | |||||||||||||||
point in time: 17 May 2024
| |||||||||||||||
Property / knows about: Human T-cell Leukemia Virus Type 1 Infection / qualifier | |||||||||||||||
prevalence: 4
| |||||||||||||||
Property / knows about: Human T-cell Leukemia Virus Type 1 Infection / reference | |||||||||||||||
Revision as of 17:02, 24 May 2024
Research Geologist with the Geosciences and Environmental Change Science Center
- Joseph Colgan
- Joseph P. Colgan
- J D Colgan
- J. P. Colgan
- J. Colgan
Language | Label | Description | Also known as |
---|---|---|---|
English | Joseph Colgan |
Research Geologist with the Geosciences and Environmental Change Science Center |
|
Statements
12 May 2024
12 May 2024
0 references
30 January 2024
17 May 2024
105
1 reference
1 reference
1 reference
17 May 2024
45
1 reference
1 reference
17 May 2024
30
1 reference
17 May 2024
27
1 reference
17 May 2024
14
1 reference
17 May 2024
1 reference
17 May 2024
1 reference
17 May 2024
1 reference
17 May 2024
1 reference
1 reference
17 May 2024
1 reference
17 May 2024
1 reference
17 May 2024
1 reference
17 May 2024
1 reference
17 May 2024
1 reference
1 reference
17 May 2024
1 reference
17 May 2024
1 reference
1 reference
17 May 2024
1 reference
1 reference
1 reference